Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Cash & Current Investments: 2009-2024

Historic Cash & Current Investments for Ani Pharmaceuticals (ANIP) over the last 15 years, with Dec 2024 value amounting to $144.9 million.

  • Ani Pharmaceuticals' Cash & Current Investments rose 81.11% to $262.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $775.2 million, marking a year-over-year decrease of 7.14%. This contributed to the annual value of $144.9 million for FY2024, which is 34.47% down from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Cash & Current Investments of $144.9 million as of FY2024, which was down 34.47% from $221.1 million recorded in FY2023.
  • In the past 5 years, Ani Pharmaceuticals' Cash & Current Investments registered a high of $221.1 million during FY2023, and its lowest value of $12.9 million during FY2020.
  • Over the past 3 years, Ani Pharmaceuticals' median Cash & Current Investments value was $144.9 million (recorded in 2024), while the average stood at $139.7 million.
  • In the last 5 years, Ani Pharmaceuticals' Cash & Current Investments crashed by 79.36% in 2020 and then soared by 718.38% in 2021.
  • Yearly analysis of 5 years shows Ani Pharmaceuticals' Cash & Current Investments stood at $12.9 million in 2020, then surged by 718.38% to $105.3 million in 2021, then crashed by 49.45% to $53.2 million in 2022, then skyrocketed by 315.38% to $221.1 million in 2023, then plummeted by 34.47% to $144.9 million in 2024.